LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Cloud DX Wins Competitive RFP, Signs Contract with Alberta Health Services

September 28, 2023 | Last Trade: C$0.13 0.00 0.00

Cloud DX can now deliver digital Remote Patient Monitoring (dRPM) solutions to clients via Hospitals and via the Central Zone Primary Care Network in Alberta.

News in Summary

  • Cloud DX is the winner of a competitive Request For Proposal (RFP) to provide digital Remote Patient Monitoring (dRPM) hardware and services to Alberta Health Services (AHS).
  • AHS is Canada's first and largest provincewide, integrated health system, responsible for delivering to health services to more than 4.4 million people.
  • Cloud DX works with AHS to enable remote monitoring of patients at various sites for use cases that include chronic disease management, post-surgical recovery at home, and general medical virtual hospital care.
  • This new contract has a duration of 2 years with a 1-year renewal option. It is Cloud DX's 21st contract or contract extension to be announced in 2023, vs 28 in all of 2022.

KITCHENER, ON / ACCESSWIRE / September 28, 2023 / Cloud DX (TSXV:CDX) (OTCQB:CDXFF), a leading North American provider of Remote Patient Monitoring services as part of the Cloud DX Connected HealthTM Virtual Care Platform is pleased to announce that it has been selected through a competitive RFP process as a provider of digital Remote Patient Monitoring (dRPM) products and services to Alberta Health Services (AHS).

AHS has deployed the Cloud DX Connected HealthTM platform since May 2020, under a series of contracts signed during and after the COVID pandemic. Now, Cloud DX has won the competitive RFP to continue as a provider of dRPM devices and services to the provincial health authority.

Digital Remote Patient Monitoring is used generally to support outcomes for patients with complex chronic conditions that include chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF) and comorbidities including hypertension, obesity, and diabetes.

Connected Health by Cloud DX includes our award-winning, patient facing mobile application, easy-to-use Health Canada licensed medical devices, smart software that gathers data from and connects to each patient at home, and comprehensive clinical workflows that improve both the efficiency of care delivery and healthcare outcomes for patients.

Clients across North America now deploy Cloud DX Connected Health for chronic disease management, post-surgical monitoring, pulmonary and cardiac rehabilitation, diabetes, and palliative care use cases.

dRPM using Cloud DX Connected Health has been shown, most recently in the peer-reviewed PCV-RAM-1 study, to dramatically reduce post-surgical medication errors, severe pain scores, ER visits and hospital readmissions.

According to official stats from the Canadian Institute for Health Information (www.cihi.ca) Patient Cost Estimator, exacerbation of chronic conditions resulted in over 11,000 hospital admissions in Alberta in 2021 averaging approx. 7 days each.

Recent research, including a series of studies at Hamilton Health Sciences in Hamilton ON, has shown that dRPM using Cloud DX Connected Health can reduce the average length of a hospital admission by 1.9 days on average.

Cloud DX is SOC 2 compliant and meets or exceeds Alberta Health Information Act (HIA) privacy and security regulations protecting personal health information.

This is the 21st contract or extension announced so far in 2023 by Cloud DX vs 28 contracts / extensions announced in all of 2022.

Robert Kaul, Founder and CEO of Cloud DX stated. "Cloud DX is very pleased to have been awarded this competitive dRPM contract with Alberta Health Services. Combined with the recently announced contract awards from Alberta Central Zone Primary Care Network and the Mohawk Medbuy shared services organization, Connected Health by Cloud DX is now, more than ever, the preferred dRPM solution for hospitals, physicians, community paramedics and provincial health authorities across Canada. With this announcement, our mission to make healthcare better for everyone in Canada takes another giant stride forward."

About Cloud DX

Accelerating digital healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health™ remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, winner of "2022 Top Innovator" from Canadian Business, a 2021 "Edison Award" winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." Cloud DX is an exclusive partner to Medtronic Canada, Teladoc Health Canada, and leading hospital procurement agent Mohawk Medbuy.

*Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomized controlled trial. BMJ 2021:374:n2209 Sept 2021.

https://www.bmj.com/content/374/bmj.n2209

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cloud DX Investor Site https://ir.clouddx.com/overview/default.aspx

Social Links

Twitter https://twitter.com/CloudDX

Facebook https://www.facebook.com/clouddxinc/

LinkedIn https://www.linkedin.com/company/cloud-dx/

Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Marketing Enquiries
Phone 888-543-0944
This email address is being protected from spambots. You need JavaScript enabled to view it.

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
Phone 647-881-8418
This email address is being protected from spambots. You need JavaScript enabled to view it.

Officer responsible for this Press Release:

Robert Kaul
Chief Executive Officer
Phone 888-543-0944
This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. In particular, this news release includes certain forward-looking statements concerning the terms of the contract extension, the expected proceeds therefrom, as well as management's objectives, strategies, beliefs and intentions.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the Company's the ability of the Company to fulfill the terms of and derive the benefits from the contract extension.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.

C4 Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB